Brought to you by 
Esteve Pharmaceuticals, S.A.
https://www.esteve.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Esteve Pharmaceuticals, S.A.
Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Towa Completes Deal For Pensa
Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.
Long Hot Summer For Novel Drug Reviews Forecast At US FDA
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
US FDA ‘Public Health’ Approach To Opioids May Open Up Pricing Debates
Latest effort by FDA to re-set reviews for novel opioid analgesics is off to a rocky start after three advisory committee reviews. One unintended consequences may already be apparent: by taking a broad, public health perspective on new formulations, the agency may be inviting arguments based on price.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Esteve Teijin Healthcare (ETH)
- Laboratorios del Dr. Esteve, S.A.